Organization
Pharmanet/i3, Indianapolis, Indiana, United States
1 abstract
Abstract
A PHASE 2 STUDY OF MULTIPLE SUBCUTANEOUS DOSES OF LY2439821, AN ANTI-IL-17 MONOCLONAL ANTIBODY, IN PATIENTS WITH RHEUMATOID ARTHRITIS IN TWO POPULATIONS: NAÏVE TO BIOLOGIC THERAPY OR INADEQUATE RESPONDERS TO TUMOR NECROSIS FACTOR ALPHA INHIBITORS Org: Eli Lilly and Company, Pharmanet/i3, Indianapolis, Indiana, United States,